Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

View:
Post by TheMadMonk on Oct 22, 2021 5:58pm

Otena

Where did the one-billion-dollar valuation for Otena come from?  Is this something the company said that they are looking for, was it what an analyst said it is worth, or is it just what people here feel like they would like to see for it?
Comment by fox7mf on Oct 22, 2021 6:10pm
Just opinions. The pivot from chronic to acute represents a smaller market for Otena. Dan says the market they are now pursuing represents $13b annually & they're confident, if successful, Otena could capture 20% of said market. So, I believe Otena would go for closer to $2.5b.
Comment by MrMugsy on Oct 23, 2021 4:30pm
Fox7 ... seems the $13B is absent the label expansion strategy for migraine, dental and menstral pain. Migraine alone could be a $2B industry. Therefore, numbers could be different from the $13B ... but weren't provided. Tough to say.
Comment by WalkOverTheStrt on Oct 24, 2021 6:23pm
Is patent length on Otenal for acute same as chronic (ending 2032)? Slide deck changed.
Comment by MrMugsy on Oct 24, 2021 6:57pm
From the latest news release ... - New patent application aimed at extending otenaproxesul’s IP protection into the 2040s https://www.businesswire.com/news/home/20211014005408/en/Antibe-Therapeutics-Provides-Update-on-Otenaproxesul-and-Expanded-Drug-Pipeline
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities